Keyword: Vasant Narasimhan
Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.
Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.
Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.
Novartis needs to trace its ethics woes to their roots and apply its stated values to real-life decisions, experts say. Even then, change takes time.
Novartis CEO pledges to inform the FDA of any "credible allegation" of data integrity problem with its drug filings within five business days.
Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis better
The Senate Finance Committee chair is investigating Novartis' handling of manipulated Zolgensma data and its decision to delay telling the FDA.
Novartis faced a fresh scandal this week with revelations AveXis scientists manipulated Zolgensma data. On Wednesday, execs responded.
Having managed the H1N1 vaccine supply crisis, Vas Narasimhan thought his exec experience had prepared him for the CEO job—until he started doing it.